TABLE OF CONTENTS
Volume 38, Issue 5 (September (1) 2006)
Review
Strategies to enhance immune function in hematopoietic transplantation recipients who have fungal infections FREE
A Safdar
Bone Marrow Transplant 38: 327-337; doi:10.1038/sj.bmt.1705439
Original Articles
Autografting
Clinical and molecular characteristics of patients with non-amyloid light chain deposition disorders, and outcome following treatment with high-dose melphalan and autologous stem cell transplantation FREE
K Weichman, L M Dember, T Prokaeva, D G Wright, K Quillen, M Rosenzweig, M Skinner, D C Seldin and V Sanchorawala
Bone Marrow Transplant 38: 339-343; advance online publication, July 24, 2006; doi:10.1038/sj.bmt.1705447
Interferon-
after autologous stem cell transplantation in pediatric patients with advanced Hodgkin's lymphoma FREE
D Petropoulos, L L Worth, C A Mullen, S Lockhart, M Choroszy and K W Chan
Bone Marrow Transplant 38: 345-349; doi:10.1038/sj.bmt.1705458
Graft-Versus-Host Disease
Nephrotic syndrome associated with chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation FREE
P Reddy, K Johnson, J P Uberti, C Reynolds, S Silver, L Ayash, T M Braun and V Ratanatharathorn
Bone Marrow Transplant 38: 351-357; advance online publication, July 24, 2006; doi:10.1038/sj.bmt.1705446
Post transplant persistence of host cells augments the intensity of acute graft-versus-host disease and level of donor chimerism, an explanation for graft-versus-host disease and rapid displacement of host cells seen following non-myeloablative stem cell transplantation? FREE
E Hirshfeld, L Weiss, J Kasir, M Zeira, S Slavin and M Y Shapira
Bone Marrow Transplant 38: 359-364; advance online publication, July 24, 2006; doi:10.1038/sj.bmt.1705449
Muromonab-CD3 (Orthoclone OKT3®), methylprednisolone and cyclosporine for acute graft-versus-host disease prophylaxis in allogeneic bone marrow transplantation FREE
M Benekli, T Hahn, B T Williams, M Cooper, H N Roy, P Wallace, C Stewart, B Bambach and P L McCarthy Jr
Bone Marrow Transplant 38: 365-370; advance online publication, July 24, 2006; doi:10.1038/sj.bmt.1705450
Prospective endoscopic evaluation for gastrointestinal graft-versus-host disease: determination of the best diagnostic approach FREE
B Thompson, D Salzman, J Steinhauer, A J Lazenby and C M Wilcox
Bone Marrow Transplant 38: 371-376; doi:10.1038/sj.bmt.1705453
Post-Transplant Complications
Prolonged thrombocytopenia after allogeneic hematopoietic stem cell transplantation: associations with impaired platelet production and increased platelet turnover FREE
R Yamazaki, M Kuwana, T Mori, Y Okazaki, Y Kawakami, Y Ikeda and S Okamoto
Bone Marrow Transplant 38: 377-384; doi:10.1038/sj.bmt.1705444
Letters to the Editor
Allogeneic stem cell transplantation from donors with mosaic Turner syndrome FREE
K N Manola, C Sambani, D Karakasis, I Baltathakis, N Zoumbos and A Symeonidis
Bone Marrow Transplant 38: 385-386; doi:10.1038/sj.bmt.1705456
Laryngeal stenosis associated with chronic graft-versus-host disease following unrelated bone marrow transplantation FREE
M Hirokawa, M Kume, T Wu, K Ishikawa and K-i Sawada
Bone Marrow Transplant 38: 387-388; advance online publication, July 24, 2006; doi:10.1038/sj.bmt.1705451
Treatment of severe therapy-resistant acute graft-versus-host disease with human adipose tissue-derived mesenchymal stem cells FREE
B Fang, Y P Song, L M liao, Q Han and R C Zhao
Bone Marrow Transplant 38: 389-390; advance online publication, July 31, 2006; doi:10.1038/sj.bmt.1705457
Severe intestinal graft-versus-host disease following autologous stem cell transplantation FREE
J Kline, K van Besien, J Nathanson, A Noffsinger and A Artz
Bone Marrow Transplant 38: 391-392; doi:10.1038/sj.bmt.1705460
Strongyloidiasis after unrelated nonmyeloablative allogeneic stem cell transplantation FREE
M H Qazilbash, N T Ueno, C Hosing, M De Lima, J Cortes, A Massaro, Z Rivera, M Deavers, J A Adachi and R E Champlin
Bone Marrow Transplant 38: 393-394; advance online publication, July 17, 2006; doi:10.1038/sj.bmt.1705448
An assessment of the RIFLE criteria for acute renal failure following myeloablative autologous and allogeneic haematopoietic cell transplantation FREE
J A Lopes, S Jorge, S Silva, E de Almeida, F Abreu, C Martins, J A do Carmo, J F Lacerda and M M Prata
Bone Marrow Transplant 38: 395; doi:10.1038/sj.bmt.1705461
Corrigenda
Ideal rather than actual body weight should be used to calculate cell dose in allogeneic hematopoietic stem cell transplantation FREE
S Singhal, L I Gordon, M S Tallman, J N Winter, A M Evens, O Frankfurt, S F Williams, D Grinblatt, L Kaminer, R Meagher and J Mehta
Bone Marrow Transplant 38: 397; doi:10.1038/sj.bmt.1705476
Does younger donor age affect the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies beneficially? FREE
J Mehta, L I Gordon, M S Tallman, J N Winter, A M Evens, O Frankfurt, S F Williams, D Grinblatt, L Kaminer, R Meagher and S Singhal
Bone Marrow Transplant 38: 397; doi:10.1038/sj.bmt.1705477
